RH Genotype Matched Red Cells for Patients With Sickle Cell Disease and Anti-D

Study point of contact

Stella Chou, MD
215-590-0947
[email protected]
Stacey Uter, BS
2155907722
[email protected]

Locations

1 United States site

Age

> 8 Years

Phase

Early Phase 1

Study type

Interventional

Gender

All

Interventions

Biological

Compensation

Unknown

About the study

This is a pilot study to evaluate the feasibility and safety of providing RH genotype matched
D+ Red Blood Cells (RBCs) to chronically transfused patients with sickle cell disease (SCD)
who type D+ but have formed anti-D and are currently transfused with D- RBC (Red Blood Cell)
units.

participation requirements

– Subjects age > 8 years old

– Diagnosis of SCD, all genotypes

– Require chronic red cell transfusion therapy

– History of anti-D

– RH genotype predicts D+ expression

participation restrictions

– Rare RH genotype that would preclude sufficient RBC units

– Antigen negative requirements due to alloimmunization that would preclude sufficient
RBC units

Locations

  • Philadelphia, Pennsylvania, United States, Children's Hospital of Philadelphia, 19104 [Recruiting]